Newborns and infants are at risk of infection and respond sub-optimally to vaccines due in part to impaired Th1-polarizing responses of antigen-presenting cells and lymphocytes. Characterization of the underlying mechanisms may identify novel approaches to neonatal immunization. We have shown that neonatal blood plasma has higher concentrations of adenosine (Ado), an endogenous purine metabolite that acts via Ado receptors to increase cytosolic cyclic Ado mono-phosphate (cAMP) and thereby impairs Th1-polarizing immune responses. Neonatal plasma contains high concentrations of Ado-generating alkaline phosphatase (AP) and 5'ectonucleotidase CD73 while containing less Ado deaminase (ADA) than adult plasma, resulting in higher Ado concentrations at birth. Monocyte (Mo)-derived dendritic cells (MoDCs) are sensitive to Ado inhibition and express cell-associated Ado-generating (CD73) and metabolizing (ADA) enzymes. To better simulate endogenous Ado-based regulation of neonatal immune responses, we have developed an autologous three-dimensional neonatal tissue construct (NTC) and a corresponding adult tissue construct (ATC), comprised of extracellular matrix, autologous plasma, and an overlying endothelium upon which cryopreserved cord blood- or peripheral blood-mononuclear cells or CD33-selected Mos extravasate and autonomous MoDC development and activation can be studied. The project objective is to characterize the impact of neonatal purine metabolism on immune responses to adjuvants, including Toll-like receptor (TLR) agonists, and vaccines, by pursuing the following Specific Aims:
In Aim 1, we will assess the relative contribution of AP, CD73 and ADA to Ado accumulation in human neonatal vs. adult blood plasma. We will employ thin layer chromatography, pharmacologic inhibitors, enzyme immunodepletion, and high performance liquid chromatography. The ontogeny of purine-metabolizing enzymes will be characterized using neonatal and infant plasma samples.
In Aim 2, we will determine effects of soluble and cell-associated AP, CD73 and ADA on activation of autonomously generated MoDCs. We will employ the novel NTC, interrogating the ability of adjuvants and vaccines, such as Bacillus Calmette-Guerin (BCG), hepatitis B vaccine, and pneumoccal conjugate vaccine to induce ADA, modulate Ado levels, and trigger differentiation and activation of mature MoDCs as measured by migration, up-regulation of co-stimulatory molecules, and induction of Th1/Th2/Th17- polarizing cytokines.
In Aim 3, we will characterize enhancing effects of Ado-refractory adjuvants, TLR8 agonists and ADA, on Ag-specific neonatal vaccine responses in vitro. We will employ co-culture of NTC-derived MoDCs and autologous lymphocytes in vaccine antigen prime, boost, and challenge assays using the NTC. These studies will provide insight into neonatal immunity, establish novel platforms for studying immune ontogeny, assess Ado-refractory adjuvants, and inform neonatal vaccine development.

Public Health Relevance

Over 2,000,000 newborns and young infants die due to infection every year, in part due to their relatively weak immune responses. Our project makes use of blood components to model immune responses of newborns and infants to vaccines. By studying mechanisms and factors that impair immune responses early in life, we hope to identify more effective ways to immunize newborns, thereby protecting them from infection and enhancing public health.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI100135-02
Application #
8532818
Study Section
Special Emphasis Panel (ZAI1-LGR-I (J1))
Program Officer
Prabhudas, Mercy R
Project Start
2012-08-16
Project End
2015-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
2
Fiscal Year
2013
Total Cost
$426,300
Indirect Cost
$181,300
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Strunk, Tobias; Inder, Terrie; Wang, Xiaoyang et al. (2014) Infection-induced inflammation and cerebral injury in preterm infants. Lancet Infect Dis 14:751-62
Jans, Jop; Vissers, Marloes; Heldens, Jacco G M et al. (2014) Fc gamma receptors in respiratory syncytial virus infections: implications for innate immunity. Rev Med Virol 24:55-70
Palmer, Christine D; Ninkovi?, Jana; Prokopowicz, Zofia M et al. (2014) The effect of stable macromolecular complexes of ionic polyphosphazene on HIV Gag antigen and on activation of human dendritic cells and presentation to T-cells. Biomaterials 35:8876-86
Levy, Ofer; Wynn, James L (2014) A prime time for trained immunity: innate immune memory in newborns and infants. Neonatology 105:136-41
Dowling, David J; Levy, Ofer (2014) Ontogeny of early life immunity. Trends Immunol 35:299-310
Levy, Ofer; Netea, Mihai G (2014) Innate immune memory: implications for development of pediatric immunomodulatory agents and adjuvanted vaccines. Pediatr Res 75:184-8
Kollmann, Tobias R; Levy, Ofer; Hanekom, Willem (2013) Vaccine-induced immunity in early life. Vaccine 31:2481-2
Pettengill, Matthew; Robson, Simon; Tresenriter, Megan et al. (2013) Soluble ecto-5'-nucleotidase (5'-NT), alkaline phosphatase, and adenosine deaminase (ADA1) activities in neonatal blood favor elevated extracellular adenosine. J Biol Chem 288:27315-26
Dowling, David J; Tan, Zhen; Prokopowicz, Zofia M et al. (2013) The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. PLoS One 8:e58164
Power Coombs, Melanie R; Kronforst, Kenny; Levy, Ofer (2013) Neonatal host defense against Staphylococcal infections. Clin Dev Immunol 2013:826303

Showing the most recent 10 out of 12 publications